Continuous Glucose Monitoring Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

The Global Continuous Glucose Monitoring Market was valued at USD 10.9 billion in 2024 and is estimated to grow at a CAGR of 16% to reach USD 47.1 billion by 2034, driven by the increasing prevalence of diabetes and the demand for real-time, user-friendly monitoring technologies. CGM systems, which allow round-the-clock tracking of glucose levels, are gaining traction across various healthcare settings. These systems typically use a minimally invasive sensor placed beneath the skin to monitor interstitial glucose, transmitting the data to digital devices for easy tracking.

With rising awareness about diabetes management and the global shift toward preventive care, the adoption of continuous glucose monitoring (CGM) systems is accelerating rapidly. Both patients and healthcare professionals are increasingly turning to CGM solutions to enable better glycemic control, reduce complications, and improve long-term health outcomes. The ability to continuously monitor glucose levels in real time, along with smart alerts and data-sharing capabilities, is transforming diabetes care by empowering individuals with actionable insights. As healthcare systems worldwide emphasize patient-centered and tech-enabled solutions, CGM technology is emerging as a cornerstone of modern diabetes management.

The continuous improvements in sensor accuracy and functionality have played a key role in transforming the CGM market. In 2024, the sensors segment generated USD 5.5 billion and is expected to grow at a CAGR of 16.1% through 2034. Advancements in biosensor technology have enabled smaller, more precise sensors that not only monitor glucose but can also track other biomarkers, offering a broader view of the user's metabolic health. Increased comfort, enhanced data precision, and better wearability prompt users to transition from traditional glucose monitoring methods to CGM systems.

Home care has emerged as a primary application area, contributing USD 8.8 billion and holding an 81% share in 2024, fueled by the convenience these systems offer. Real-time alerts, integration with smartphones, and the ability to easily share data with healthcare professionals make CGM devices a practical choice for patients managing diabetes at home. In addition, shifts toward remote care have further increased adoption, with consumers showing a strong preference for at-home monitoring solutions that reduce dependence on clinical visits.

United States Continuous Glucose Monitoring Market accounted for USD 4.9 billion in 2024, driven by the rising number of people living with diabetes and greater insurance coverage that has improved the affordability and accessibility of CGM systems. Supportive Medicare policies and reimbursement expansions have enabled broader patient adoption, including among seniors and low-income groups. At the same time, the U.S. market is benefiting from continuous innovation in wearable health tech, leading to smaller, more comfortable sensors with extended wear time and enhanced data accuracy.

Prominent companies in the Global Continuous Glucose Monitoring Market include Dexcom, Medtronic, Abbott Laboratories, Senseonics, F. Hoffmann-La Roche, Sinocare, Med Trust, Medtrum Technologies, Zhejiang POCTech, i-SENS, and A. Menarini Diagnostics. To enhance market presence, CGM manufacturers invest in R&D to develop next-generation sensors with improved accuracy, smaller sizes, and longer wear times. Many are forming strategic alliances with digital health platforms and mobile app developers to enhance device connectivity and data integration. Others are expanding their global footprint through regional partnerships and acquiring smaller firms to diversify product portfolios and speed up innovation.